
|Articles|October 1, 2007
- Volume 0 0
Seven Deadly Sins AND HOW TO AVOID THEM: Interviews
Advertisement
- ARRIVING LATE?Set 2 alarm clocks, and allow more than enough travel time.
- DRESSING INFORMALLY?Have a dry-cleaned, conservative business suit ready to go.
- POOR EYE CONTACT?Concentrate on maintaining eye contact throughout the interview. Eye contact is not the same asstaring.
- ASKING ONLY SELF-SERVING QUESTIONS?Prepare questions that show your interest in the position or company.
- DEMONSTRATING IGNORANCE ABOUT THE HIRING COMPANY?Do some background research on the companybefore the interview.
- USING EVERYDAY LANGUAGE AND SPEECH PATTERNS?Practice interviewing and using professional terminologywhere appropriate. Avoid ?like,? ?ya know,? ?really,? and ?OK?? when they are simply fillers.
- FAILING TO ADDRESS THE QUESTION ASKED?Be careful to listen to the question and understand it before answering.
Articles in this issue
almost 19 years ago
PRUITT-SCHUTTE COMPETITION STRIVES FOR EXCELLENCEalmost 19 years ago
DOCTOR TOM'S TOP TEN TIPS: PASSING THE PHARMACY BOARDSalmost 19 years ago
PHARMACY GROUPS JOIN TOGETHER TO IMPROVE SERVICEalmost 19 years ago
STUDENT POLITICAL INVOLVEMENT DOES IMPACT PHARMACYalmost 19 years ago
Seven Deadly Sins AND HOW TO AVOID THEM: R?sum?almost 19 years ago
OWNING YOUR OWN PHARMACY: A PLAN AND PARTNERSHIP COME TOGETHERalmost 19 years ago
TECHNOLOGY EXPANDS PHARMACY REACH IN UNDERSERVED RURAL AREASalmost 19 years ago
PARTNERSHIP PROGRAMS?A WIN-WIN FOR COMMUNITY PHARMACISTSalmost 19 years ago
GOOD NEIGHBOR PHARMACY REWARDS EXCELLENCEalmost 19 years ago
WELCOME TO INDEPENDENT PHARMACYAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First OTC Acetaminophen–Naproxen Combination for 12-Hour Pain Relief
2
Thoracic Radiotherapy Added to Atezolizumab Raises Fatal Toxicity Risk in ES-SCLC
3
Q&A: Pharmacists' Role in CKD Grows as Finerenone Eyes Label Expansion
4
Lilly Prepares for Retatrutide FDA Filing Following Additional Phase 3 Data in Diabetes, CVD
5










































































































